← All Signals

🏥 FDA: CareFusion 213, LLC — Class II

healthcarebearishSource: FDA
85%Confidence
0Views
FDASource
2026-05-27Date

Summary

A second sterility issue for BD's PurPrep product amplifies quality control concerns, potentially leading to broader market share loss. Repeated failures may trigger FDA enforcement actions.

Actionable: Evaluate BD's corrective actions and potential litigation costs; reduce holdings if further recalls emerge.

AI Confidence: 85%

Data Points

firmCareFusion 213, LLC
classificationClass II
statusOngoing
distributionNationwide in the USA
productBD PurPrep, Povidone-iodine 8.3% w/w (0.83% available iodine) with isopropyl alcohol 72.5% w/w Sterile Solution, 25x26mL Applicators per carton. Caref

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now